Sensitive and specific markers for insulin resistance, hyperandrogenemia, and inappropriate gonadotrophin secretion in women with polycystic ovary syndrome: a case-control study from Bahrain by Golbahar, Jamal et al.
© 2012 Golbahar et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Women’s Health 2012:4 201–206
International Journal of Women’s Health
Sensitive and specific markers for insulin 
resistance, hyperandrogenemia, and inappropriate 
gonadotrophin secretion in women with 
polycystic ovary syndrome: a case-control  
study from Bahrain
Jamal Golbahar1,2,*
Maha Al-Ayadhi2,*
Negalla Mohan Das2
Khalid Gumaa2
1Department of Molecular Medicine, 
Al-Jawhara Centre for Genetic 
Diagnosis and Research, 2Department 
of Medical Biochemistry, College of 
Medicine and Medical Sciences, AGU, 
Manama, Bahrain 
*These authors contributed equally to 
this article
Correspondence: Jamal Golbahar 
Department of Molecular Medicine, 
Al-Jawhara Centre for Genetic Diagnosis 
and Research, College of Medicine and 
Medical Sciences, AGU, Manama, Bahrain 
Tel +973 17237317 
Fax +973 17271090 
Email jamalgo@agu.edu.bh
Background: In women with polycystic ovary syndrome (PCOS), despite a high prevalence 
of insulin resistance, hyperandrogenemia, and disturbances in the secretion of gonadotrophin, 
the principal causes of biochemical abnormalities and the best endocrine markers for PCOS 
have not been fully identified.
Subjects and methods: Serum levels of insulin, glucose, follicle-stimulating hormone (FSH), 
luteinizing hormone (LH), total testosterone, estrogen, sex hormone-binding capacity (SHBG), 
and other related indices such as homeostasis model assessment, insulin glucose ratios, LH/FSH 
ratios, and the free androgen index (FAI) were determined and compared in women with PCOS 
(n = 50) and women without PCOS (n = 50).
Results: In multivariate logistic regression analyses, among all insulin resistance indices, only 
hyperinsulinemia (odds ratio [OR] = 2.6; confidence interval [CI]: 1.3–5.2; P = 0.008) was 
significantly and independently associated with PCOS when adjusted for body mass index 
(BMI), hyperandrogenemia, and LH/FSH ratios. The LH/FSH ratio (OR = 5.4; CI: 1.2–23.0, 
P = 0.03) was the only marker among those indices for inappropriate gonadotrophin secretion 
that significantly and independently associated with PCOS when adjusted for BMI and 
  hyperinsulinemia. Among those indices for hyperandrogenemia, FAI (OR = 1.1; CI: 1.0–2.7; 
P = 0.02) and SHBG (OR = 1.2; CI: 1.2–3.4; P = 0.03) were significantly and independently 
associated with PCOS when adjusted for BMI and hyperinsulinemia. In addition, receiver 
operating characteristic analysis showed that the best predictive markers for PCOS were insulin 
(area under the curve [AUC] = 0.944; CI: 0.887–0.989), FAI (AUC = 0.932; CI: 0.895–0.993), 
SHBG (AUC = 0.924; CI: 0.87–0.978), and LH/FSH ratios (AUC = 0.906; CI: 0.821–0.965).
Conclusion: For insulin and LH/FSH ratios, FAI, and SHBG seemed the best predictors and 
markers for insulin resistance, inappropriate gonadotrophin secretion, and hyperandrogenemia, 
respectively, with high sensitivity and specificity for identifying Bahraini women with and 
without PCOS.
Keywords: polycystic ovary syndrome, insulin resistance, gonadotrophin, hyperandrogenemia, 
diagnostic markers
Introduction
Polycystic ovary syndrome (PCOS) is one of the most common female endocrine 
disorders affecting women of reproductive age, with a prevalence of about 5%–10% 
in the general population.1 It is a heterogeneous disorder of variable mild to severe 
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disturbances that affect reproductive, endocrine, and 
  metabolic functions.2 PCOS is characterized by menstrual 
disturbances due to hirsutism, chronic anovulation or oligo-
ovulation, and acne due to excessive androgen production 
(hyperandrogenemia).3 In addition, insulin resistance has 
been reported to be a major contributor in the pathogenesis 
of PCOS, although the mechanism of this association is poorly 
understood.4,5 PCOS patients are often referred to endocrinolo-
gist, gynecologist, and dermatologist clinics; however, there 
is no information regarding the best indices for the diagnosis 
of insulin resistance, hyperandrogenemia, or inappropriate 
gonadotrophin secretion in Bahraini women with PCOS. 
Diagnosis and treatment of these conditions in PCOS women 
are costly and place a socioeconomic burden on government-
supported health systems around the world.6
Obesity, particularly the abdominal phenotype, is one of 
the most often reported clinical features in PCOS women 
and about 50% of PCOS women are reported to be either 
overweight or obese. Indeed, it has been suggested that losing 
5% body weight will result in an improvement in the regular-
ity of the menstrual cycle and the correction of hirsutism in 
women with PCOS.7 The association of obesity with the 
pathogenesis of PCOS has been extensively reported in the 
literature and there are more than 50 genes reported to be 
involved in the regulation of ovarian steroidogenesis, which 
may contribute to obesity and insulin/glucose homeostasis 
in PCOS women.7–9
There are conflicting reports regarding the best predictors 
of insulin resistance, hyperandrogenemia, and inappropriate 
gonadotrophin secretion in PCOS women in different 
  populations. To find the best markers for insulin resistance 
in PCOS women, insulin, homeostasis model assessment 
(HOMA), and insulin/glucose ratio (IGR) have been investi-
gated in a large number of studies.10–13 In PCOS women, 
hyperandrogenemia and inappropriate gonadotrophin secre-
tion can be assessed by measuring testosterone, sex hormone-
binding capacity (SHBG), and the free androgen index (FAI), 
as well as luteinizing hormone (LH), follicle-stimulating 
hormone (FSH), and LH/FSH ratios.14–23 It has been suggested 
that hormonal abnormalities such as hyperandrogenemia and 
inappropriate gonadotrophin secretion in PCOS women are 
not only related to the reproductive system but may also be 
associated with the features of metabolic syndrome and insulin 
resistance.24 In classical PCOS, 30%–90% of patients have 
inappropriate gonadotrophin secretion, with a higher LH/FSH 
ratio (2–3:1) than normal women in the follicular phase.25
In this case-control study, the best indices for insulin 
resistance that discriminate between women with and without 
PCOS – hyperandrogenemia and inappropriate gonadotro-
phin secretion – were investigated.
Subjects and methods
Participants
Fifty PCOS women aged 16–38 years enrolled in the study 
after being recruited from the health centers in the Salmania 
Medical Complex, at the main hospital in Manama, Kingdom 
of Bahrain, from February to October 2008.
Inclusion criteria for PCOS cases were based on the 
Rotterdam 2003 criteria.26 For diagnosis of PCOS, at least 
two of the following symptoms needed to be observed: 
oligoovulation or anovulation (usually manifested as oli-
gomenorrhea or amenorrhea); elevated levels of circulating 
androgens (hyperandrogenemia) or their clinical manifesta-
tions (hyperandrogenemia); and polycystic ovaries, as 
defined by ultrasonography (ultrasonographic criteria: mean 
of 12 follicle numbers per ovary of both ovaries or ovarian 
volume of 10 mL, 0.5 × length × width × thickness).26 
  Inclusion criteria for controls were a normal menstrual cycle 
with no history of insulin resistance, hyperandrogenemia, 
inappropriate gonadotrophin secretion, hirsutism, ovarian 
failure, or any other endocrine or major organ disorders. In 
this study, of the 65 control subjects, 15 were excluded 
because nine had insulin resistance, two had ovarian failure, 
two had hyperprolactinemia, and two were in the luteal 
phase. Hirsutism was assessed using modified Ferriman–
Gallwey scoring, in which a score . 7 indicates hirsutism.27 
Fasting blood samples were collected in the follicular phase 
(cycle days 2–8) in all participants.
This study was approved by the Research and Ethics 
Committee of the College of Medicine and Medical Sciences, 
AGU, Bahrain, and written informed consent was obtained 
from all patients and controls.
Analytical methods
Serum insulin was measured by microparticle enzyme immu-
noassay and plasma glucose was measured using the hexoki-
nase and glucose-6-phosphate dehydrogenase method. HOMA 
was calculated by multiplying fasting blood glucose (mmol/L) 
with fasting insulin (µU/mL) and dividing by 22.5.
Serum LH, FSH, total testosterone, and estrogen were 
determined by electrochemiluminescence immunoassay. 
SHBG was measured by noncompetitive immunoassays. 
Serum insulin was measured by microparticle enzyme 
immunoassay.
The FAI was calculated by dividing total testosterone by 
SHBG and multiplying by 100.
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Statistical analysis
The normality of distribution of all the variables was assessed 
using the Kolmogorov–Smirnov test and any positively or 
negatively skewed variables were logarithmically trans-
formed to reduce kurtosis before geometric means were 
calculated. Subsequently, the logarithmic transformations 
were used in further statistical analysis.
Logistic regression analysis was used to determine the 
association of obesity, insulin resistance, hyperandrogenemia, 
and inappropriate gonadotrophin secretion with PCOS. 
  Multiple logistic regression analysis was used to determine 
the association of PCOS with hyperinsulinemia, adjusted for 
obesity, hyperandrogenemia, and LH/FSH ratios. It was also 
used to determine the association of hyperandrogenemia with 
PCOS, adjusted for obesity and hyperinsulinemia. Receiver 
operating characteristic (ROC) analysis was used to determine 
the best predictors for insulin resistance, hyperandrogenemia, 
and inappropriate gonadotrophin secretion in PCOS women. 
ROC curves were constructed by plotting the sensitivity (true-
positive) on the ordinate as a function of the complement of 
specificity (false-positive) for all possible cutoff values of the 
diagnostic tests. Greater deviation toward the left upper corner 
of the curve indicated better detection of PCOS.
All reported P values were two tailed and P values ,0.05 
were considered statistically significant. The statistical 
analyses were performed using SPSS software (v 19; IBM 
Corp, Armonk, NY).
Results
The biometric and biochemical parameters determined in 
PCOS and healthy control women are illustrated in Table 1. 
Table  1  Anthropometry  and  biochemical  characteristics  of 
PCOS patients and controls
Characteristics Patients  
(n = 50)
Controls  
(n = 50)
P value
Age (years) 27.7 ± 5.3 28.3 ± 6.4 0.597
BMI (kg/m²) 34.1 ± 7.2 27.0 ± 6.2 ,0.001
FSH (IU/L) 5.0 ± 1.2 6.0 ± 1.5 ,0.001
LH (IU/L)* 6.20 ± 5.6 5.27 ± 2.4 0.130
LH/FSH Ratio 1.5 ± 0.82 0.97 ± 0.34 ,0.001
E2 (pmol/L)* 212.1 ± 137 182.9 ± 98 0.139
Testosterone  
(nmol/L)*
1.42 ± 1.32 0.95 ± 0.75 0.004
SHBG (nmol/L)* 20.4 ± 17.1 35.53 ± 23.1 ,0.001
FAI* 7.38 ± 3.1 2.77 ± 1.7 ,0.001
Glucose (mmol/L) 5.1 ± 0.71 4.8 ± 0.45 0.017
Insulin (µU/mL)* 15.0 ± 3.0 6.5 ± 1.7 ,0.001
HOMA-IR* 3.3 ± 1.4 1.4 ± 0.9 ,0.001
IGR 4.54 ± 1.9 1.41 ± 0.50 ,0.001
Note: *Data presented as geometric mean ± standard deviation.
Abbreviations: BMI, body mass index; E2, estradiol; FAI, free androgen index; FSH, 
follicle-stimulating  hormone;  HOMA-IR  (Insulin  Resistance),  homeostasis  model 
assessment-Insulin Resistance; IGR, insulin glucose ratio; LH, luteinizing hormone; 
SHBG, sex hormone-binding capacity.
Table 2 Associations of PCOS with obesity, insulin resistance, hyperandrogenemia, and inappropriate gonadotrophin secretion, 
determined by multiple logistic regression analyses
Variables Crude 
OR (95% CI)
P Adjusted for 
obesity 
OR (95% CI)
P Adjusted for obesity  
and hyperinsulinemia
OR (95% CI)
P Adjusted for obesity, 
hyperandrogenemia  
and LH/FSH ratios
OR (95% CI)
P
BMI 1.2 (1.1–3) ,0.0001
LH 1.1 (3.7–18.5) 0.001 1.3 (1.1–1.3) 0.003 1.5 (0.9–6.2) 0.06
FSH 1.7 (1.4–2.9) 0.001 2.6 (1.4–5.7) 0.01 0.66 (0.83–0.57) 0.31
LH/FSH 5.0 (1.4–4.2) 0.001 4.5 (1.1–24.2) 0.03 5.4 (1.2–23.0) 0.03
Testosterone 2.4 (0.31–1.91) 0.002 2.2 (1.1–4.0) 0.01 1.3 (0.25–6.6) 0.765
SHBG 1.1 (1.0–1.1) 0.0001 1.4 (1.4–3.1) 0.01 1.2 (1.2–3.4) 0.03
FAI 1.3 (1.1–1.5) 0.001 1.2 (1.1–1.4) 0.01 1.1 (1.0–2.7) 0.02
E2 1.0 (0.99–1.1) 0.157 1.0 (0.99–1.0) 0.628 1.0 (0.99–1.0) 0.509
HOMA 1.6 (2.8–25.6) 0.001 1.3 (2.4–42.1) 0.02 0.89 (2.9–760) 0.135
Insulin 2.3 (1.5–3.4) 0.0001 2.1 (1.2–3.8) 0.001 2.6 (1.3–5.2) 0.008
IGR 3.5 (3.7–26.4) 0.001 3.1 (4.9–32.6) 0.004 0.62 (0.87–45.0) 0.234
Abbreviations: BMI, body mass index; CI, confidence interval; E2, estradiol; FAI, free androgen index; FSH, follicle-stimulating hormone; HOMA, homeostasis model 
assessment; IGR, insulin glucose ratio; LH, luteinizing hormone; OR, odds ratio; SHBG, sex hormone-binding capacity.
Body mass index (BMI), HOMA, insulin, glucose, estradiol 
(E2), testosterone, estrogen, FAI, and LH/FSH ratios were 
significantly higher in women with PCOS than in controls, 
whereas FSH and SHBG were significantly lower in the 
cases than in the controls. Multivariate logistic regression 
analyses showed that high BMI, HOMA, insulin, LH/FSH 
ratios, testosterone, FAI, low FSH, and SHBG were signifi-
cantly associated with PCOS (Table 2). However, when 
adjusted for high insulin, HOMA and FAI were indepen-
dently associated with PCOS. Furthermore, hyperinsuline-
mia was determined to be independently associated with 
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PCOS when adjusted for obesity, hyperandrogenemia, and 
LH/FSH ratios.
ROC analyses using area under the curve revealed that 
the best predictive markers for insulin resistance, hyperan-
drogenemia, and inappropriate gonadotrophin in PCOS 
women were determined to be insulin, FAI, SHBG and 
LH/FSH ratios, respectively (Table 3).
Discussion
In this study, various predictors and discriminators for 
diagnosis of PCOS in Bahraini women were identified using 
multiple logistic regression and ROC analyses. The use of 
ROC curves to investigate the predictive power of endocrine 
parameters in the diagnosis of PCOS has been reported in 
a large number of studies.14–23 The independent association 
of obesity and hyperinsulinemia with PCOS women 
observed in this study has also been extensively reported 
in different populations. In a recent study reported in this 
group of PCOS Bahraini women, insulin, leptin/adiponectin, 
and adiponectin/leptin ratios were reported to be the best 
marker to distinguish women without PCOS from those 
with PCOS.28 However, consistent with recent reported 
studies,10–13,29 among the markers indicating insulin resis-
tance (insulin, HOMA, and IGR), insulin was independently 
associated with PCOS and it was the best marker for dif-
ferentiating women with and without PCOS. This indicates 
that women with PCOS need to be evaluated for other 
related conditions associated with hyperinsulinemia, includ-
ing type 2 diabetes mellitus, hypertension, dislipidemia, 
and atherosclerosis.10 Medications that reduce circulating 
insulin have been   suggested as effective therapies for PCOS 
and sufficient evidence has accumulated to justify the clini-
cal use of insulin-sensitizing agents in the management of 
women with PCOS.11
One of the main aims of this study was to investigate 
whether total testosterone, estrogen, SHBG, and FAI were 
appropriate markers for assessing hyperandrogenemia in 
patients with PCOS. In this study, low SHBG was inde-
pendently associated with PCOS when adjusted for obesity 
and hyperinsulinemia. In addition, ROC analysis showed 
that SHBG is one of the best markers of hyperandrogen-
emia and thus for the diagnosis of PCOS women. These 
results are consistent with recent studies suggesting the 
discriminative power of SHBG in PCOS women.15,19 
Hyperinsulinemic patients with PCOS were demonstrated 
to have decreased SHBG at the hepatic level. It has been 
suggested that a high insulin level in circulation may lead 
to the reduction of SHBG and that this consequently causes 
an increase in the concentration of free androgen in 
circulation.19
Androgen status in women has been assessed by FAI, 
which is also a measure for assessing the availability of 
circulating testosterone in females with hirsutism. In this 
study, FAI was also independently associated with PCOS 
and ROC analysis showed that it is one of the best markers 
for hyperandrogenemia in PCOS women, which is consistent 
with the results reported in previous studies of different 
populations.14,18–21
In this study, the independent association of high 
LH/FSH ratios with PCOS was observed when controlled 
for obesity and hyperinsulinemia. Several studies have sug-
gested that the increased LH and LH/FSH ratios in PCOS 
women are not related to BMI or adiposity, and LH-pulse 
amplitude has been reported to be higher in lean PCOS 
women compared with obese PCOS women.30 In this group 
of PCOS women, ROC analysis also showed that the predic-
tive cover of LH/FSH ratio was better than that of LH/FSH 
ratio for diagnosing inappropriate gonadotrophin secretion 
in PCOS, a finding consistent those reported for some other 
studies of different populations.14,17,18 The mechanisms of 
high LH/FSH ratios in PCOS women are not clear; however, 
it has been suggested that they might be related to primary 
defects in the hypothalamic and pituitary functions in PCOS 
women.30
One of the limitations of this study is that BMI was sig-
nificantly higher in PCOS women than in the controls; 
therefore, it can be argued that due to the lack of matching 
Table 3 Analysis of receiver operating characteristics for the 
best predictors of PCOS
Test-result variables AUC ROC 95% CI
Insulin 0.944 0.887–0.989
FAI 0.932 0.895–0.993
SHBG 0.924 0.871–0.978
LH/FSH 0.906 0.821–0.965
IGR 0.786 0.698–0.864
HOMA 0.693 0.582–0.805
Testosterone 0.666 0.553–0.779
FSH 0.674 0.564–0.784
FBS 0.615 0.506–0.725
E2 0.603 0.481–0.724
LH 0.593 0.472–0.714
Abbreviations: AUC, area under the curve; BMI, body mass index; CI, confidence 
interval;  E2,  estradiol;  FAI,  free  androgen  index;  FBS,  fasting  blood  sugar;  FSH, 
follicle-stimulating hormone; HOMA, homeostasis model assessment; IGR, insulin 
glucose ratio; LH, luteinizing hormone; OR, odds ratio; ROC, receiver operating 
curve; SHBG, sex hormone-binding capacity.
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BMIs in the controls and cases, the hyperinsulinemia 
observed in this group of PCOS women could be due to 
obesity.   Consequently, this study was inconclusive as to 
whether hyperinsulinemia can be considered a marker for 
distinguishing women with PCOS from those without it. 
However, results from this study’s multiple logistic 
  regression analysis showed that hyperinsulinemia was inde-
pendently and significantly associated with PCOS when 
adjusted for obesity.
Conclusion
High insulin, FAI, LH/FSH ratios, and low SHBG can dis-
criminate between women with and without PCOS, with 
both high sensitivity and high specificity. This is the first 
study to describe the best indices of insulin resistance, 
hyperandrogenemia, and inappropriate gonadotrophin secre-
tion in Bahraini women with PCOS. Larger studies are 
required to investigate the significance of these findings for 
the routine clinical work-up of PCOS women. However, the 
results from this study may serve as a valuable adjunct to 
the diagnostic criteria used in scientific studies of this het-
erogeneous syndrome.
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